The Remote Monitoring of Gout Feasibility Study

The ReMonit Gout Feasibility Study

In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.

In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.

Inclusion Criteria:

• Male or non-pregnant, non-nursing female >18 years of age at screening
• Patients with a clinical diagnosis of gout
• Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
• Serum urate level >360 μmol/L at inclusion
• Having a smartphone/tablet

Exclusion Criteria:

• Contraindication for urate lowering therapy
• Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance <45 mL/min); severe infection or gastrointestinal bleed
• Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
• Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult